When was Genenta Science founded?

Genenta Science was founded in 2014 and raised its 1st funding round 1 year after it was founded.

Where is Genenta Science located?

Genenta Science is headquartered in Milan, Italy.

How many employees does Genenta Science have?

As of Sep 30, 2026, the latest employee count at Genenta Science is 19.

Is Genenta Science a funded company?

Genenta Science is a funded company, having raised a total of $33.6M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Mar 05, 2015.

When was the latest funding round of Genenta Science?

Genenta Science's latest funding was a $***** Post IPO round on Mar 19, 2025, with participation from 1 investor.

Where does Genenta Science rank among its competitors?

Genenta Science ranks 393rd amongst 3605 active competitors, of which 1179 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Genenta Science?

Genenta Science's top competitors include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Among them, Immuneel secured the most recent funding round in June, 2026.

Genenta Science - 2026 Company Profile, Team, Funding & Competitors

Genenta Science is a public company based in Milan (Italy), founded in 2014 by Bernhard Gentner and Luigi Naldini. It operates as a Developer of lentivirus-based gene and cell therapies for cancer. Genenta Science has raised $33.6M in funding from Qianzhan and Mediobanca. The company has 3605 active competitors, including 1179 funded and 837 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Kite Pharma.

Company Details

Developer of lentivirus-based gene and cell therapies for cancer. The lead candidateTemferon is a lentivirus-based hematopoietic stem progenitor cell immuno-gene therapy for Glioblastoma, solid tumor, and hematological malignancies. Also, has Tie2-Expressing Monocytes immunotherapies for multiple cancer treatment.

Website: www.genenta.com/
Social

Key Metrics

Founded Year

2014

Location

Milan, Italy

Stage

Public

Total Funding

$33.6M in 4 rounds

Latest Funding Round

Post IPO, Mar 19, 2025, $*****

Investors

Qianzhan & 5 more

Ranked

393^rd among 3605 active competitors

Employee Count

19 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3289 more

Exit Details

Public

View Genenta Science's full profile

Genenta Science got listed on Dec 15, 2021.

Click here to take a look at Genenta Science's IPO in detail

Genenta Science has raised a total funding of $33.6M over 4 rounds. Its first funding round was on Mar 05, 2015. Its latest funding round was a Post IPO round on Mar 19, 2025 for $*****. 1 investor participated in its latest round. Genenta Science has 6 institutional investors.

Here is the list of recent funding rounds of Genenta Science:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 19, 2025	8182789	Post IPO	3637674	3290102	9995441	9219721
Sep 11, 2019	4243086	Series C	8485002	8912925	1355289	2686002
Sep 13, 2017	4596490	Series B	8055950	5578699	7204630	1203328

Access funding benchmarks and valuations. Sign up today!

View details of Genenta Science's funding rounds and investors

The founders of Genenta Science are Bernhard Gentner and Luigi Naldini.

Here are the details of Genenta Science's key team members:

Bernhard Gentner: Co-Founder of Genenta Science.
Luigi Naldini: Co-Founder of Genenta Science.

View details of Genenta Science's Founder profiles and Board Members

Genenta Science's employee count trend

Genenta Science has 19 employees as of Sep 26. Here is Genenta Science's employee count trend over the years:

Employee count trend for Genenta Science

Uncover Genenta Science's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Genenta Science include Jazz Pharmaceuticals, BeiGene and Kite Pharma. Here is the list of Top 10 competitors of Genenta Science, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	77/100
3rd	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	76/100
4th	Attovia 2023, Fremont (United States), Public	Developer of antibody-based therapeutics for immune-mediated diseases and oncology	$255M	Deep Track Capital, Goldman Sachs Asset Management ... & 13 others	72/100
5th	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
6th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
8th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	71/100
393rd	Genenta Science 2014, Milan (Italy), Public	Developer of lentivirus-based gene and cell therapies for cancer	$33.6M	Mediobanca, Growth Engine & 4 others	55/100